May 13 |
Leap Therapeutics: The DisTinGuish Trial Provides A Near-Term Catalyst
|
May 13 |
Leap Therapeutics Inc (LPTX) Q1 2024 Earnings: Financial Resilience Amidst Clinical Progress
|
May 13 |
Leap Therapeutics Reports First Quarter 2024 Financial Results
|
Apr 29 |
Pipeline Moves: Investigator-led trial of Lilly’s merestinib in solid tumours terminated
|
Apr 11 |
Leap Therapeutics announces $40 million private placement
|
Apr 11 |
Leap Therapeutics Announces $40 Million Private Placement
|
Mar 20 |
Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks
|
Mar 18 |
Leap Therapeutics files for $200M mixed shelf offering
|
Mar 18 |
Leap Therapeutics GAAP EPS of -$0.46 beats by $0.10
|
Mar 18 |
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
|